Industry Outlook 2025: Evolving Pipelines and Supply Chain

In the post-COVID world, pharmaceutical companies have been looking to reconfigure their supply chains and work with global partners, according to Krishna Kanumuri, CEO of Sai Life Sciences. “I think people are looking for the next-generation partners they need [for their] business, which is a challenge, both for providers as well as customers, because customers need to develop new relationships, need to get [these up to speed], and still need to deliver on their programs,” Kanumuri says.

“I think [the] pharma industry itself is looking at what their pipelines [will] look like going forward,” Kanumuri says. “If you look three, four years back, pharma was talking about gene therapy, cell therapy. But right now, thanks to GLP-1s [glucagon-like peptide-1], I think the three main modalities which are getting very exciting at this point are peptides, oligonucleotides, and ADCs [antibody drug conjugates], along with small molecules which seem to be back, and also the fact that all these modalities, about 80% of the work is actually small molecules.”

Click the video above to watch the full interview.

About the speaker

Krishna Kanumuri is CEO of Sai Life Sciences.